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Fibrosing mediastinitis (FM) and IgG4-related disease (IgG4-RD) are two ﬁbroinﬂammatory disorders with potentially
overlapping clinical and radiological features. In this paper, we looked for histopathologic features of IgG4-RD and enumerated
inﬁltrating IgG4-positive plasma cells within mediastinal tissue biopsies from FM patients. We identiﬁed 15 consecutive FM
surgical mediastinal tissue biopsies between 1985 and 2006. All patients satisﬁed the clinical and radiological diagnostic criteria
for FM. All patients had either serological or radiological evidence of prior histoplasmosis or granulomatous disease, respectively.
Formalin-ﬁxed paraﬃn-embedded tissue sections of all patients were stained for H&E, IgG, and IgG4. Three samples met the
predeﬁned diagnostic criteria for IgG4-RD. In addition, characteristic histopathologic changes of IgG4-RD in the absence of
diagnostic numbers of tissue inﬁltrating IgG4-positive plasma cells were seen in a number of additional cases (storiform cell-
rich ﬁbrosis in 11 cases, lymphoplasmacytic inﬁltrate in 7 cases, and obliterative phlebitis/arteritis in 2 cases). We conclude that up
to one-third of histoplasmosis or granulomatous-disease-associated FM cases demonstrate histopathological features of IgG4-RD
spectrum.WhetherthesechangesoccurasthehostimmuneresponseagainstHistoplasmaorrepresentamanifestationofIgG4-RD
remains to be determined. Studies to prospectively identify these cases and evaluate their therapeutic responses to glucocorticoids
and/or other immunosuppressive agents such as rituximab are warranted.
1.Background
IgG4-related disease (IgG4-RD) is recognized to include
a growing number of ﬁbroinﬂammatory disorders [1–5].
Histopathologic evaluation typically demonstrates distinc-
tive cellular ﬁbrosis organized in an irregular whorled
pattern(oftenreferredtoas“storiformﬁbrosis”),obliterative
phlebitis/arteritis, and prominent lymphoplasmacytic tissue
inﬁltration [6]. Tissue immunostaining and serum IgG-
subclassassessmentcharacteristicallyreveallargenumbersof
IgG4 producing plasma cells and elevated serum IgG4 levels,
respectively [6].
IgG4-RD was ﬁrst described in the context of autoim-
mune pancreatitis presenting with obstructive jaundice due
to a space-occupying lesion within the pancreas [7, 8].
Since these initial reports, IgG4-RD has been demonstrated
to involve various other organs including the biliary tree
(sclerosing cholangitis), salivary (sclerosing sialadenitis),
and lacrimal glands (sclerosing dacroadenitis) in isolation
or in combination (multisystem involvement) [1–5, 9].
IgG4-RD is typically characterized by clinical and radio-
graphic evidence of an idiopathic metabolically active (e.g.,
ﬂuorodeoxyglucose-avid) space-occupying lesions within
diﬀerent organs [1–5, 9, 10]. Therapeutically, patients with
IgG4-RD typically respond to immunosuppressive therapy
with glucocorticoids [11].
Fibrosingmediastinitis(FM),alsocalledsclerosingmedi-
astinitis, is a rare syndrome characterized by an aggressive
ﬁbroinﬂammatory process within the mediastinum [12–
15]. Progressive ﬁbrosis caused by the proliferation of2 International Journal of Rheumatology
invasive ﬁbrous tissue within the mediastinum frequently
results in compression and functional compromise of vital
mediastinal structures [13–15]. Consequently, FM can lead
to substantial disease-related morbidity and perhaps even
increased mortality [13, 15].
Although the pathogenesis of FM remains unknown,
radiographic, serologic, or histopathologic evidence of prior
Histoplasma capsulatum infection can often be documented.
In endemic areas of North America, the majority of
FM cases are thought to represent a rare hypersensitivity
reaction to this infection [13–18]. Additional infectious
triggers implicated in the pathogenesis of FM include
other fungal and mycobacterial organisms associated with
granulomatous mediastinitis [13–18]. Finally, there are
rare immune-mediated (idiopathic) and drug-induced (e.g.,
methysergide) cases of FM [13–18]. Interestingly, patients
with idiopathic immune-mediated FM frequently have other
disease manifestations such as retroperitoneal ﬁbrosis or
Riedels thyroiditis, all of which have been associated with
the IgG4-RD spectrum [6, 13–18]. Except for selected
patients with the idiopathic immune-mediated variant of
FM, therapeutic successes using systemic glucocorticoids
and other immunosuppressive agents are exceptionally rare
[14].
Chest computed tomography in “granulomatous-
infection-associated” FM characteristically demonstrates
focal, commonly calciﬁed, and most commonly right-
sided mediastinal mass lesions. This contrasts the diﬀuse
noncalciﬁed mediastinal inﬁltration classically seen in
idiopathic immune-mediated or drug-induced cases
[19, 20]. Given the high diagnostic yield of chest radiological
evidence of a focal, calciﬁed mediastinal mass compromising
other mediastinal structures, diagnostic tissue biopsies are
currently largely reserved to exclude alternative diagnoses
such as mediastinal malignancies [14, 20].
Mediastinal lymphadenopathy is one of the most fre-
quent extrapancreatic disease manifestations in patients with
IgG4-RD [21, 22]. However, up to date only a single case
of FM attributed to IgG4-RD disease has been reported in
the medical literature. This Japanese patient had a clinical
and radiographic presentation consistent with idiopathic
immune-mediated FM but demonstrated histopathological
changes typical of IgG4-RD, had an elevated serum IgG4
level, and responded favorably to glucocorticoid therapy
[23]. Fibrosis within the mediastinum without compression
of mediastinal structures has been reported in the context of
patients with other disease manifestations of IgG4-RD [24–
26].
We and others have recently demonstrated that mediasti-
nal biopsies from consecutive patients with FM frequently
contain large numbers of inﬂammatory cells including a
high number of CD138- (syndecan-1-) positive plasma
cells [12, 14]. Consequently, FM is now considered to
represent a ﬁbroinﬂammatory rather than a purely ﬁbrotic
disease process. Based on these ﬁbroinﬂammatory changes
associated with the local accumulation of plasma cells, we
hypothesized that a subset of FM cases may belong in the
IgG4-RD spectrum and demonstrate histopathological and
immunological changes consistent with IgG4-RD.
2. Patients andMethods
A search of the Mayo Clinic pathology database for a
histopathological diagnosis of FM (we used the search
terms of ﬁbrosing mediastinitis, sclerosing mediastinitis, and
mediastinal ﬁbrosis) between 1985 and 2006 identiﬁed 21
biopsy specimens in the Mayo Clinic tissue registry. The
medical records of these cases were reviewed and FM cases
were deﬁned clinically by the presence of chest radiological
evidenceofaninﬁltrative(crossingtissueplanes)mediastinal
process associated with the invasion or obstruction of medi-
astinal structures. Based upon evidence of coexisting malig-
nancies, two patients (one with malignant thymoma and
one with desmoplastic mesothelioma) were excluded. The
histopathology of the remaining cases was independently
reviewed by two of the investigators (TVC and ESY) and a
diagnosis of FM was conﬁrmed in 15 patients. Four cases
were excluded due to the absence of invasive ﬁbrosis. The
clinical and radiographic features and the characterization of
adaptive immune response (immunostaining for CD3, CD8,
CD20, CD138, and S100) of these cases have been described
in detail elsewhere [14].
Immunostaining was performed using a DAKO auto-
staining system (DAKO, Carpinteria, CA, USA). The mon-
oclonal mouse anti-human IgG4 antibody (clone HP6025,
dilution1:100,Zymed,SanFrancisco,CA,USA)wasusedto
stain formalin-ﬁxed, paraﬃn-embedded tissue sections. In a
similar fashion, IgG staining was performed on consecutive
tissue sections using the polyclonal rabbit anti-human IgG
antibody (IS512, dilution 1:10,000, DAKO, Carpinteria, CA,
USA).
The presenceand number of IgG- and IgG4-positive cells
was evaluated in all 15FM cases. To enumerate IgG and
IgG4-positiveplasmacells,theentireslidewasscannedatlow
powerfortheareaswiththehighestIgG4-positiveplasmacell
density. For each case, the three high power ﬁelds (hpf) with
thehighestdensitywerephotographedusingamagniﬁcation
of 40x (Nikon Eclipse E400 microscope, ﬁeld diameter
0.55mm and Olympus DP70 camera, 0.0645mm2). The
corresponding areas were also photographed on the IgG-
stained slides. The number of IgG4- and IgG-positive
plasma cells was determined in 3hpf by manually counting
positive cells on the photomicrographs and cell numbers
were averaged. The number of IgG4-positive cells/hpf was
determined,andthefractionofIgG4-positivecellsofallIgG-
positive plasma cells [%] was calculated for each case.
3. Deﬁnitions
3.1. Clinical Deﬁnition of FM. Presence of radiological
evidence of an inﬁltrative, space-occupying mediastinal
process with associated pulmonary vascular, airway, superior
vena cava (SVC), or esophageal compression. Patients with
mediastinal malignancies and/or prior mediastinal radiation
therapy were excluded [14, 20].
3.2. Histological Case Deﬁnition of FM. A histopathological
diagnosis of FM required the presence of extensive tissue
ﬁbrosis.ThisﬁbroustissuetypicallyinﬁltratesandobliteratesInternational Journal of Rheumatology 3
Table 1: Radiological, microbiological and histological characteristics of the 15FM patients.
Age/gender Histological features




25/M Deﬁnite Right mediastinal mass Suggestive Absent
32/M Deﬁnite Calciﬁed left hilar mass Conclusive Present
65/F Deﬁnite Right mediastinal mass Conclusive Present
51/F Absent Calciﬁed left cervical and right hilar
mass Conclusive Present
31/F Absent Calciﬁed right mediastinal mass Suggestive Absent
27/F Absent Calciﬁed right mediastinal mass Conclusive Present
27/F Absent Diﬀuse mediastinal inﬁltration Suggestive Present
48/F Absent Left mediastinal mass Suggestive Present
35/M Absent Calciﬁed bilateral hilar masses Conclusive Present
43/F Absent Right mediastinal mass Not available Present
44/M Absent Calciﬁed anterior mediastinal mass Not available Absent
27/F Absent Calciﬁed right mediastinal mass Conclusive Present
59/F Absent Calciﬁed right mediastinal mass Conclusive Present
36/F Absent Calciﬁed right mediastinal mass Conclusive Absent
58/F Absent Calciﬁed right mediastinal mass Not available Absent






Figure 1: Histopathological changes and IgG4 immunostaining demonstrate an overlap between FM and IgG4-RD in a subset of patients
(n = 3), (a). cell rich, storiform ﬁbrosis, (b). vascular inﬂammation and (c). IgG4 positive plasma cells. (representative images selected from
3 patients).
adipose tissue with or without patchy mononuclear immune
cell inﬁltration in the absence of malignancy.
3.3. Histoplasma Capsulatum Infection. A conclusive diagno-
sis of infection was assumed in the presence of a positive
fungal stain (Grocott methenamine silver (GMS)) or culture
of the biopsy tissue specimens and/or serologic titer ≥1:32
and/or presence of an M or H band by complement ﬁx-
ation/immunodiﬀusion. A suggestive diagnosis was deﬁned
as a serologic titer >1:8 and/or radiological features (pul-
monary, splenic, and/or hepatic granulomas) suggestive of
previous granulomatous infection.
3.4. Granulomatous Disease. Patients with radiological fea-
tures of prior granulomatous disease, histological evidence
ofgranulomatousinﬂammation,oralocalizedcalciﬁedmass
lesion within the mediastinum were classiﬁed as previous
granulomatous disease [20].4 International Journal of Rheumatology
3.5. IgG4-RD. IgG4-RD was deﬁned using the following
deﬁnition: d e ﬁ n i t ec a s eo fI g G 4 - R D : at least two of the
following three histological features: (1) lymphoplasmacytic
inﬁltrate, (2) storiform-type ﬁbrosis, or (3) obliterative
phlebitis/arteritis plus ≥50 IgG4-positive cells/hpf with an
IgG4+/IgG+ ratio ≥40%. Probable case of IgG4-RD:o n e
histological feature plus ≥50 IgG4-positive cells/hpf with
an IgG4+/IgG+ ratio ≥40%. Unlikely case of IgG4-RD:
remaining cases. This deﬁnition is based on the consensus
recommendations provided by a panel of experts during
the International Symposium on IgG4-Related Disease,
Boston, MA, October 2011 (http://www2.massgeneral.org/
pathology/symposium/IgG4 related systemic dis.asp).
The Mayo Clinic Institutional Review Board (IRB)
approved the study.
4. Results
All 15 patients underwent surgical resection/debulking (7
patients) or surgical biopsy (8 patients) at Mayo Clinic,
Rochester, MN, between 1985 and 2006 [14].
Histopathological examination universallydemonstrated
the proliferation of ﬁbrous tissue with associated inﬁltration
of the surrounding mediastinal fat and soft tissues. Surgical
sampling of the adjacent lymph nodes was performed
in 8 of 15 cases. In 6 cases, the lymph node samples
revealed extensive perinodal ﬁbrosis, extending more than
2mm beyond the capsule. One case exhibited only mild
perinodal sclerosis with ﬁbrous reaction less than 2mm.
In another case, perinodal scarring was absent. In 10 of
15 cases histopathologic evidence of prior granulomatous
disease with associated necrosis (with or without calciﬁ-
cation) and a surrounding dense ﬁbrotic rim was identi-
ﬁed. GMS staining detected characteristic yeast forms for
Histoplasma capsulatum in 6 of 13 cases. The organisms
were typically detected in the necrotic areas of granulomas
(Table 1).
Three cases met the predeﬁned diagnostic histological
criteria for deﬁnite IgG4-RD (FM IgG4-RD) (Figure 1).
The absolute numbers of IgG4-positive plasma cells and
the IgG4+/IgG+ ratios are summarized in Figure 2.N o
cases of probable IgG4-RD were identiﬁed. Interestingly,
despite the absence of the required number and ratio of
IgG4-positive plasma cells, characteristic histopathological
ﬁndings of IgG4-RD such as cell-rich storiform ﬁbrosis and
lymphoplasmacytic inﬁltration were frequently present in
the remaining non-IgG4-RD cases (Table 2).
Unfortunately, serum IgG4 levels were not available
for any of these patients and none of them was treated
with glucocorticoids or other immunosuppressants. The
demographic, clinical, and radiological characteristics are
summarized in Table 3. Based upon the geographic location
of our institution in the Midwestern United States, it is not
surprisingthatallofourcaseshadevidenceofpriorgranulo-
matous infections, predominantly histoplasmosis (Table 1).
There were no idiopathic immune-mediated cases among
our 15FM patients. Overall there were no signiﬁcant dif-
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Figure 2: Number of IgG4-positive plasma cells and the corre-
sponding IgG4+/IgG+ ratios in FM patients (n = 15, 3 patients had
no IgG4 positive plasma cells).







IgG4/IgG ratio, case (%)
3 (100) 0 (0)
Lymphoplasmacytic
inﬁltrate, cases (%) 3 (100) 7 (58)
Storiform, cell-rich ﬁbrosis,
cases (%) 3 (100) 11 (91)
Obliterative phlebitis/
arteritis, cases (%) 2 (66) 2 (16)
(Table 3). None of our patients had disease manifestations of
IgG4-RD outside the mediastinum.
5. Discussion
The precise etiology of FM remains indeterminate. It likely
represents a clinical-pathological syndrome attributable to
various triggers including infectious pathogens causing
granulomatous mediastinitis, drug toxicity and idiopathic
immune-mediated cases [13–15]. The majority of FM
cases respond suboptimally to antimicrobial, immunosup-
pressive, and antiﬁbrotic treatments [13–15]. Therapeutic
responses of patients with histoplasmosis/granulomatous-
disease-associated FM are exceedingly rare. Better under-
standing of the pathogenesis in speciﬁc cases of FM may
ultimately result in improved individualized therapies for
subgroups of patients.
By deﬁnition, IgG4-RD is currently considered an idio-
pathic ﬁbroinﬂammatory disorder [1, 2, 4, 6, 9]. It is
characterized by the expansion of IgG4-producing plasma
cells. The triggers and pathogenesis of IgG4-RD remain
undeﬁned[1,2,4,6,9].Yet,thediseaseistypicallyresponsive
to glucocorticoid therapy [1, 2, 4, 6, 9]. Furthermore,International Journal of Rheumatology 5




(N = 12) P-value
Age (Median, range (years)) 32 (25–65) 39.5 (27–59) NS
Gender (Women, number of cases (%)) 1 (33) 10 (83) NS
Radiological disease localization
Right 2 7
NS Left 0 1
Bilateral 1 4
Organ compression
Superior vena cava 1 3
NS Pulmonary vascular 1 3
Airway 1 5
Esophagus 0 1
Histoplasmosis (N = 13)
Conclusive 2 7
NS Suggestive 1 2
Absent 0 1
refractory IgG4-RD cases frequently improve following
the depletion of B-lymphocytes with rituximab [11, 27].
Unfortunately, current clinical, serologic, and pathological
diagnostic criteria for IgG4-RD, especially outside the pan-
creas, lack high diagnostic accuracy. The diagnostic criteria
for most other organ systems including the mediastinum are
exclusively based on expert consensus or extrapolated from
observations in the pancreas, salivary, and lacrimal glands.
Consequently, a diagnosis of IgG4-RD requires the exclusion
of all diseases that can mimic the disorder. Important
mimics include malignancies, infections, and vasculitides
[28–30].
The clinical, radiological, and pathological presentation
of FM as a metabolically active space-occupying ﬁbro-
inﬂammatory disease process within the mediastinum is
highly compatible with the disease manifestations of IgG4-
RD in other organs such as the pancreas and the sali-
vary glands. Herein we demonstrate that a subset of
histoplasmosis/granulomatous-disease-associated FM cases
exhibits the histopathological and immunological charac-
teristics consistent with a deﬁnite diagnosis of IgG4-RD:
lymphoplasmacytic inﬁltration, storiform ﬁbrosis, oblitera-
tive phlebitis/arteritis, and an accumulation of IgG4-positive
plasma cells (≥50 cells/hpf and ≥40% of IgG4/IgG-positive
plasma cells). Therefore, this subgroup of FM cases may
be part of the ever-expanding disease spectrum of IgG4-
RD, and perhaps respond favorably to immunosuppressive
therapy with glucocorticoids or rituximab. Interestingly,
the tissue samples of these patients also contained a large
number of CD20-positive B-lymphocytes [14]. Alternatively,
these histopathological ﬁndings and the expansion of IgG4-
positive plasma cells within the tissue biopsies of these
patients may represent a subset of an IgG4 dominant
ﬁbroinﬂammatory response triggered by histoplasmosis or
other granulomatous diseases. It is conceivable, that this
response pattern is indicative of the presence of chronic
infection or persistence of foreign antigens within the tissue.
Our study has several limitations.
Due to the retrospective design our analysis of the
clinical, radiological and serologic data is constrained by the
data documented in the medical records by a diverse team
of care providers. Furthermore, the infrequent utilization of
diagnostic tissue biopsies and surgical debulking procedures
in FM patients restricted our analysis of the histopathologic
pattern and number of IgG4-positive plasma cells to a
relatively small subset of FM patients (small study size).
However, we have previously demonstrated that these 15
patients were representative of a large FM cohort treated
at a Midwestern tertiary referral center [14]. Our study
does not include any tissue specimens from patients with
idiopathic immune-mediated FM, which based on the
common association with other IgG4-RD and response to
immunosuppressive therapy would perhaps be even more
likely to represent a manifestation of IgG4-RD. Moreover,
serum IgG4 measurements were not performed in these
patients,andtherapeuticglucocorticoidusewasnotreported
for any of these patients.
In summary, we conclude that there is an overlap
of the histopathologic features between histoplasmosis/
granulomatous-disease-associated FM and IgG4-RD. A sub-
set,approximately20%,oftheseFMcasesmayindeedbepart
of the IgG4-RD spectrum. Although the exact pathogenesis
and natural history of these cases remains unknown and may
diﬀer from classic IgG4-RD, the prospective identiﬁcation
of this subgroup of patients with characteristic IgG4-RD
histopathology and a hyper-IgG4 immune response would
be extremely valuable. This strategy can perhaps facilitate
the identiﬁcation of a subset of FM patients more likely to
respond to immunosuppressive therapy. Consequently, we
proposetheprospectiveidentiﬁcationofthissubgroupofFM
patients based upon the presence of an elevated serum IgG4
level >140mg/dL and/or characteristic histopathological6 International Journal of Rheumatology
ﬁndings and accumulation of IgG4-positive plasma cells
within the mediastinal tissue. As the use of chest computed
tomography has largely reduced the need for routine surgical
tissue biopsies to establish a diagnosis of FM, based on the
vast experience of the successful use of endoscopic needle
biopsies for the diagnosis of IgG4-RD in the pancreas,
we recommend to obtain transbronchoscopic ultrasound-
guided needle biopsies if surgical biopsies are not needed
for diagnosis [20, 31, 32]. This approach would allow
the identiﬁcation of a patient population to prospectively
evaluatethetreatmenteﬀectsofglucocorticoidsand/orother
immunosuppressive agents such as rituximab in FM patients
with diagnostic features of IgG4-RD (FM IgG4-RD).
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